149 related articles for article (PubMed ID: 21951753)
41. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
[TBL] [Abstract][Full Text] [Related]
42. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
43. Pharmacologic management of diabetic peripheral neuropathic pain.
Iyer S; Tanenberg RJ
Expert Opin Pharmacother; 2013 Sep; 14(13):1765-75. PubMed ID: 23800105
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain.
Yuen E; Gueorguieva I; Bueno-Burgos L; Iyengar S; Aarons L
Eur J Pain; 2013 Mar; 17(3):382-93. PubMed ID: 22893563
[TBL] [Abstract][Full Text] [Related]
45. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain.
Tesfaye S; Wilhelm S; Lledo A; Schacht A; Tölle T; Bouhassira D; Cruccu G; Skljarevski V; Freynhagen R
Pain; 2013 Dec; 154(12):2616-2625. PubMed ID: 23732189
[TBL] [Abstract][Full Text] [Related]
46. Advances in the management of diabetic peripheral neuropathy.
Tesfaye S
Curr Opin Support Palliat Care; 2009 Jun; 3(2):136-43. PubMed ID: 19421063
[TBL] [Abstract][Full Text] [Related]
47. Duloxetine (Cymbalta) for diabetic neuropathic pain.
Med Lett Drugs Ther; 2005 Aug 15-29; 47(1215-1216):67-8. PubMed ID: 16103866
[TBL] [Abstract][Full Text] [Related]
48. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy.
Berger A; Dukes E; Edelsberg J; Stacey B; Oster G
Clin J Pain; 2007; 23(3):251-8. PubMed ID: 17314585
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis.
Jiang L; Xiong Y; Cui J
Contrast Media Mol Imaging; 2022; 2022():4084420. PubMed ID: 35299589
[TBL] [Abstract][Full Text] [Related]
50. Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study.
Wang YF; Chen YT; Tsai CW; Yen YC; Chen YC; Shia BC; Wang SJ
J Headache Pain; 2020 May; 21(1):54. PubMed ID: 32429883
[TBL] [Abstract][Full Text] [Related]
51. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.
Zhao Y; Chen SY; Wu N; Fraser KA; Boulanger L
Pain Pract; 2011; 11(4):381-91. PubMed ID: 21199311
[TBL] [Abstract][Full Text] [Related]
52. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
53. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Am J Health Syst Pharm; 2013 Dec; 70(24):2207-17. PubMed ID: 24296843
[TBL] [Abstract][Full Text] [Related]
54. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.
Ziegler D; Pritchett YL; Wang F; Desaiah D; Robinson MJ; Hall JA; Chappell AS
Diabetes Care; 2007 Mar; 30(3):664-9. PubMed ID: 17327338
[TBL] [Abstract][Full Text] [Related]
55. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
Matsuoka H; Makimura C; Koyama A; Otsuka M; Okamoto W; Fujisaka Y; Kaneda H; Tsurutani J; Nakagawa K
Anticancer Res; 2012 May; 32(5):1805-9. PubMed ID: 22593465
[TBL] [Abstract][Full Text] [Related]
56. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.
Armstrong DG; Chappell AS; Le TK; Kajdasz DK; Backonja M; D'Souza DN; Russell JM
Pain Med; 2007; 8(5):410-8. PubMed ID: 17661854
[TBL] [Abstract][Full Text] [Related]
57. Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions.
Augendre-Ferrante B; Picard H; Evans D; Arkoub H; Pamulapati S; Perrot S; Valensi P; Rouillon F
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):1-7. PubMed ID: 24161159
[TBL] [Abstract][Full Text] [Related]
58. Treating diabetic peripheral neuropathic pain.
Lindsay TJ; Rodgers BC; Savath V; Hettinger K
Am Fam Physician; 2010 Jul; 82(2):151-8. PubMed ID: 20642268
[TBL] [Abstract][Full Text] [Related]
59. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain.
Argoff CE; Backonja MM; Belgrade MJ; Bennett GJ; Clark MR; Cole BE; Fishbain DA; Irving GA; McCarberg BH; McLean MJ
Mayo Clin Proc; 2006 Apr; 81(4 Suppl):S12-25. PubMed ID: 16608049
[TBL] [Abstract][Full Text] [Related]
60. Duloxetine in the management of diabetic peripheral neuropathic pain.
Ormseth MJ; Scholz BA; Boomershine CS
Patient Prefer Adherence; 2011; 5():343-56. PubMed ID: 21845034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
